Related Experiment Video
Updated: Jul 7, 2026

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Proteomics-driven cancer biomarker discovery: looking to the future
Richard J Simpson1, Oliver K Bernhard, David W Greening
1Joint Proteomics Laboratory, Ludwig Institute for Cancer Research and the Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3055, Australia. Richard.simpson@ludwig.edu.au
Developing new cancer biomarkers is crucial for early detection and treatment monitoring. Overcoming challenges with blood samples by leveraging cancer tissue and cell secretomes can accelerate the discovery of novel clinical assessment tools.
Area of Science:
- Biomarker discovery
- Proteomics
- Cancer research
Background:
- Biomarkers are vital for cancer early detection, subtype stratification, and therapy monitoring.
- Despite advances in mass spectrometry (MS) proteomics, novel clinical tool discovery remains slow.
- Blood biospecimens present inherent difficulties for candidate biomarker discovery.
Purpose of the Study:
- To highlight the limitations of blood for comparative protein profiling in cancer research.
- To emphasize the advantages of using cancer tissue and cancer cell secretomes for biomarker discovery.
- To suggest strategies for enhancing the progress of novel clinical assessment tool development.
Main Methods:
- Review of current proteomics technologies and their application in cancer biomarker discovery.
- Analysis of the challenges associated with using blood as a primary biospecimen.
- Evaluation of the benefits of alternative biospecimens like cancer tissue and secretomes.
Main Results:
- Blood-based biomarker discovery faces significant technical hurdles.
- Cancer tissue and cancer cell secretomes offer more advantageous profiles for comparative analysis.
- Understanding these biospecimen differences is key to improving biomarker discovery rates.
Conclusions:
- Enhanced understanding of biospecimen limitations and advantages is critical for advancing cancer biomarker discovery.
- Leveraging cancer tissue and secretomes can overcome current limitations in blood-based proteomics.
- This approach promises to accelerate the development of novel tools for improved cancer patient outcomes.
More Related Videos
12:23Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
Published on: August 2, 2018
10:37Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
Published on: November 15, 2017
Related Concept Videos
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets